Repository and Registry of Myotonic Dystrophy Core
强直性肌营养不良核心的存储库和注册表
基本信息
- 批准号:7535919
- 负责人:
- 金额:$ 5.21万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-09-30 至 2013-08-30
- 项目状态:已结题
- 来源:
- 关键词:Animal ModelAntibodiesBioinformaticsBiologicalCaringCellsClinicalClinical DataClinical ResearchClinical assessmentsDatabasesDiseaseEnd PointFamily memberFundingGoalsModelingMyoblastsMyotoniaMyotonic DystrophyOperative Surgical ProceduresPatientsPlasmidsProviderRNARecruitment ActivityRegistriesResearchResearch PersonnelResourcesTissue SampleTransgenic OrganismsUnited States National Institutes of HealthUniversitiesimprovedmouse modelpatient registryrepositorytreatment trial
项目摘要
SCIENTIFIC RESOURCE CORE
University of Rochester Paul D Wellstone MDCRC Repository and National Registry of Myotonic Dystrophy
Patients and Family Members
The last 5 years have brought remarkable progress in our understanding of the disease mechanisms in the
myotonic dystrophies (DM1 & DM2). A relatively complete pathophysiologic understanding of these
disorders is within reach, and new treatments that can reverse myotonia in animal models of DM1 are
already available. To maximally exploit these research opportunities investigators need access to critical
biological and bioinformatic resources and to patients willing to participate in clinical studies. To achieve
these goals, we propose to combine our current Wellstone Center Repository Core and our NIH sponsored
National Registry of Myotonic Dystrophy Patients and to enhance the resources of the Registry. The
resources in the Repository include DM myoblasts, transgenic mouse models and cells derived from these
models, plasmids for expressing expanded RNA repeats and for developing new models for repeat
expansion disorders, antibodies, and tissue samples. During the currently funded operation many
investigators outside of the URMC Wellstone MDCRC as well as within our Center have used Repository
resources. A large database of information in carefully characterized DM1 patients is needed to identify
optimal endpoints for treatment trials and develop better approaches for clinical care. To accomplish this
goal we have included our National Registry of DM1 patients and family members which contains information
on 676 DM patients and has 6 years of annual clinical data on 70% of the patients. The Registry is a major
resource for recruitment for Project 1 in the renewal application and is a valuable resource to researchers
within and outside of the Wellstone MDCRC network. We plan to recruit 80 Registry patients with DM1 for
the studies of Project 1. Those patients will participate in the longitudinal clinical assessments of Project 1
that occur at 0, 12 and 36 months. These findings will enhance the value of their past and present
information in the Registry. By helping to remove barriers to research, the Registry and Repository will
improve the quality and quantity of research on DM and stimulate participation and involvement of new
investigators, patients, family members, and care providers.
科学资源核心
罗切斯特大学Paul D Wellstone MDCRC资料库和强直性肌营养不良国家登记处
患者和家属
在过去的5年里,我们在理解疾病机制方面取得了显着进展,
强直性肌营养不良(DM1和DM2)。一个相对完整的病理生理学了解这些
疾病是触手可及的,新的治疗方法,可以扭转肌强直的动物模型DM1是
已经有了。为了最大限度地利用这些研究机会,研究人员需要获得关键的
生物学和生物信息学资源以及愿意参与临床研究的患者。实现
为了实现这些目标,我们建议将我们目前的Wellstone中心知识库核心和NIH赞助的
国家强直性肌营养不良症患者登记处,并加强登记处的资源。的
资源库中的资源包括DM成肌细胞、转基因小鼠模型和源自这些模型的细胞。
用于表达扩增的RNA重复序列和用于开发新的重复序列模型的质粒
扩张性疾病抗体和组织样本在目前资助的行动中,
URMC Wellstone MDCRC以外的调查人员以及我们中心内的调查人员使用了知识库
资源需要一个大型的DM1患者信息数据库来识别
治疗试验的最佳终点,并开发更好的临床护理方法。为了实现这一
我们的目标包括我们的国家登记处的DM 1患者和家庭成员,其中包含信息
对676名糖尿病患者进行了研究,并对70%的患者进行了6年的年度临床数据。书记官处是一个主要的
在更新申请中为项目1招聘的资源,对研究人员来说是一个宝贵的资源
在Wellstone MDCRC网络内外。我们计划招募80例DM 1登记研究患者,
项目1的研究。这些患者将参与项目1的纵向临床评估
分别发生在0个月、12个月和36个月。这些发现将提升他们过去和现在的价值
登记处的资料。通过帮助消除研究障碍,登记册和存储库将
提高糖尿病研究的质量和数量,并鼓励新的参与和参与
研究者、患者、家庭成员和护理提供者。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
RICHARD T MOXLEY其他文献
RICHARD T MOXLEY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('RICHARD T MOXLEY', 18)}}的其他基金
9th International Myotonic Dystrophy Consortium Meeting
第九届国际强直性肌营养不良联盟会议
- 批准号:
8651262 - 财政年份:2013
- 资助金额:
$ 5.21万 - 项目类别:
Phase 2 Study of Mexiletine for the Treatment of Myotonic Dystrophy
美西律治疗强直性肌营养不良的 2 期研究
- 批准号:
8022616 - 财政年份:2011
- 资助金额:
$ 5.21万 - 项目类别:
8th International Myotonic Dystrophy Consortium Meeting
第八届国际强直性肌营养不良联盟会议
- 批准号:
8248432 - 财政年份:2011
- 资助金额:
$ 5.21万 - 项目类别:
Phase 2 Study of Mexiletine for the Treatment of Myotonic Dystrophy
美西律治疗强直性肌营养不良的 2 期研究
- 批准号:
8536631 - 财政年份:2011
- 资助金额:
$ 5.21万 - 项目类别:
Phase 2 Study of Mexiletine for the Treatment of Myotonic Dystrophy
美西律治疗强直性肌营养不良的 2 期研究
- 批准号:
8271228 - 财政年份:2011
- 资助金额:
$ 5.21万 - 项目类别:
Sixth International Myotonic Dystrophy Consortium Meeting
第六届国际强直性肌营养不良联盟会议
- 批准号:
7407187 - 财政年份:2007
- 资助金额:
$ 5.21万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 5.21万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 5.21万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 5.21万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 5.21万 - 项目类别:
Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 5.21万 - 项目类别:
Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 5.21万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 5.21万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
- 批准号:
10639161 - 财政年份:2023
- 资助金额:
$ 5.21万 - 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
- 批准号:
10752441 - 财政年份:2023
- 资助金额:
$ 5.21万 - 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
- 批准号:
10867639 - 财政年份:2023
- 资助金额:
$ 5.21万 - 项目类别:














{{item.name}}会员




